Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...

Sanofi to present data from Beyfortus to treat RSV diseases at IDWeek 2024 annual meeting: Paris Thursday, October 10, 2024, 12:00 Hrs [IST] Sanofi advances its ambition to protec ...

Spread of the virus is seasonal, with activity often picking up in the fall after kids go back to school. Activity usually ...

Sanofi - Aventis Groupe said that the data featured at IDWeek from several national immunization programs will reinforce the proven ...

One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years ...

Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infantsParis, October 9, ...

The most recent U.S. Food and Drug Administration inspection of Thermo Fisher's Greenville plant in May identified manufacturing issues for the respiratory syncytial virus drug Beyfortus ...

Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity and ...